Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Retraction Note: Deferiprone Treatment in Aged Transgenic Tau Mice Improves Y-Maze Performance and Alters Tau Pathology.
Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
Published: October 10, 2023
Deferiprone attenuates neuropathology and improves outcome following traumatic brain injury.
Journal: British journal of pharmacology
Published: February 10, 2022
Correction to: Deferiprone Treatment in Aged Transgenic Tau Mice Improves Y-Maze Performance and Alters Tau Pathology.
Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
Published: December 15, 2021
The Iron Chelator Deferiprone Improves the Phenotype in a Mouse Model of Tauopathy.
Journal: Journal of Alzheimer's disease : JAD
Published: November 30, 2020
Deferiprone Treatment in Aged Transgenic Tau Mice Improves Y-Maze Performance and Alters Tau Pathology.
Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
Published: November 12, 2020
The Iron Chelator Deferiprone Improves the Phenotype in a Mouse Model of Tauopathy.
Journal: Journal of Alzheimer's disease : JAD
Published: August 04, 2020
Characterising the spatial and temporal brain metal profile in a mouse model of tauopathy.
Journal: Metallomics : integrated biometal science
Published: January 07, 2020
Untangling Tau and Iron: Exploring the Interaction Between Iron and Tau in Neurodegeneration.
Journal: Frontiers in molecular neuroscience
Published: May 28, 2018
Showing 1-8 of 8
Last Updated: 09/26/2026